Ludwig

Ludwig Cancer Research is a global non-profit organization dedicated to the prevention and control of cancer through innovative basic and translational research. Founded in 1971 by Daniel K. Ludwig, the organization operates through the Ludwig Institute for Cancer Research and a network of Ludwig Centers at six major U.S. academic institutions. It is distinguished by its ability to conduct its own clinical trials and its success in spinning off biotechnology companies and partnering with major pharmaceutical firms like AbbVie and Roche. The organization's pipeline includes a diverse range of therapeutic modalities, such as monoclonal antibodies, cell therapies, and vaccines, targeting key pathways in cancer immunology and metabolism. Ludwig's research has led to significant breakthroughs in the treatment of glioblastoma, melanoma, and other solid tumors, as well as advancements in diagnostic technologies.